For a patient with internal carotid artery (ICA) terminus occlusion recanalized using a double stent retriever technique with a balloon catheter, what are the recommended loading and maintenance doses of antiplatelet agents (aspirin and clopidogrel or alternatives) and intra‑procedural anticoagulation?

Antiplatelet and Anticoagulation Dosing for ICA Terminus Occlusion Recanalized with Double Stent Retriever Technique

For a patient with ICA terminus occlusion successfully recanalized using a double stent retriever technique with balloon catheter, initiate aspirin 162-325 mg loading dose immediately (if not already given) followed by dual antiplatelet therapy (DAPT) with aspirin 81 mg daily plus clopidogrel 75 mg daily for at least 1-3 months, then transition to aspirin 81 mg daily indefinitely.

Intra-Procedural Anticoagulation

During the mechanical thrombectomy procedure, unfractionated heparin (UFH) should be administered as the primary anticoagulant 1:

• Initial bolus: 2000-5000 units IV (or weight-based 50-70 U/kg)
• Target activated clotting time (ACT): 250-300 seconds
• Monitoring: Check ACT intermittently and give additional boluses as needed to maintain therapeutic range
• Post-procedure: Heparin is typically not reversed immediately after the procedure 1

Post-Procedural Antiplatelet Therapy

Loading Doses (if not pre-treated):

Aspirin:

• 162-325 mg loading dose before or immediately after procedure 2, 3

Clopidogrel:

• 600 mg loading dose is preferred over 300 mg for faster and more complete platelet inhibition 3, 4
• The 600 mg dose achieves greater platelet inhibition with fewer low responders 4

Maintenance Therapy:

Given that this patient received stenting (double stent retriever technique implies stent placement):

DAPT regimen 3, 5:

• Aspirin 81 mg daily (preferred maintenance dose over higher doses)
• Plus clopidogrel 75 mg daily
• Duration: Minimum 1-3 months, ideally up to 6 months depending on bleeding risk

After DAPT period:

• Continue aspirin 81 mg daily indefinitely 3, 5

Critical Considerations for Neurointerventional Context

Key Differences from Cardiac Stenting:

While the provided guidelines are predominantly from cardiac literature, the neurointerventional context requires specific attention 1, 6:

1. Shorter DAPT duration may be appropriate: Recent evidence suggests 1-3 months of DAPT after carotid stenting may be sufficient 7, with no significant difference in outcomes between short-duration (≥90 days but <6 months) versus longer DAPT

2. Bleeding risk is paramount: Intracranial procedures carry higher hemorrhagic transformation risk, particularly in patients with large ischemic cores

3. Consider ticagrelor as alternative: Recent data suggest ticagrelor 180 mg loading dose followed by 90 mg twice daily may be superior to clopidogrel in preventing cerebral ischemic events, particularly in patients with intracranial atherosclerosis 6, 8

Algorithm for Decision-Making

Step 1: Immediate post-procedure (Day 0-1)

• Continue IV heparin for 12-24 hours if no hemorrhagic complications
• Initiate or continue aspirin 81-325 mg daily
• Give clopidogrel 600 mg loading dose if not pre-treated

Step 2: Days 2-90

• Aspirin 81 mg daily + clopidogrel 75 mg daily
• Monitor for bleeding complications
• Perform imaging to assess for hemorrhagic transformation

Step 3: Months 3-6

• If low bleeding risk and high thrombotic risk: Continue DAPT
• If high bleeding risk or stable: Transition to aspirin 81 mg monotherapy

Step 4: Beyond 6 months

• Aspirin 81 mg daily indefinitely 3, 5

Common Pitfalls to Avoid

1. Do not use prasugrel in patients with prior stroke/TIA (Class III: Harm) 3, 4

2. Avoid proton pump inhibitors (especially omeprazole/esomeprazole) with clopidogrel as they significantly reduce its antiplatelet effect 9

3. Do not use fondaparinux as sole anticoagulant during the procedure (Class III: Harm) 3

4. Monitor for CYP2C19 poor metabolizers: Consider alternative P2Y12 inhibitor (ticagrelor) if genetic testing reveals poor metabolizer status, as clopidogrel effectiveness is significantly reduced 9

5. Premature DAPT discontinuation dramatically increases thrombotic risk - ensure patient understands importance of adherence 3